




## Who We Are

Pathway Health is an integrated healthcare company that provides a comprehensive approach to chronic pain management by providing advanced products and clinical services to patients suffering from chronic pain and related conditions. We are committed to delivering timely access to personalized care to help improve our patients' quality of life.






## Investment Highlights



Leading partner with Canadian pharmacy companies for medical cannabis consultations, pharmacist education

- Signed agreements covering ~2,000 retail pharmacy locations nationally
- Cannabis Health Products (CHPs) development
  - CHPs market estimated >\$2 billion<sup>1</sup>




> 80,000 patient visits in 2021<sup>2</sup>

Largest medical cannabis telehealth network in Canada



3-year revenue growth -  $$600k (2018) > $12 million (2020)^3$ 



<sup>2.</sup> Annualized figure based on management's best estimate of patient visits if all acquisitions occurred on January 1, 2021.

<sup>3.</sup> These are unaudited revenue figures that reflect management's best estimate of additional revenue that would have been earned had the acquisitions of NHS, NACM Clinic and Pharmacy business and NMI occurred January 1, 2020.





## Our Business

#### **SERVICES**

## Interdisciplinary chronic pain management

- Comprehensive list of pain services
  - Interventional
  - Adding allied health (physio, chiro, massage therapy)
- Expansion to include mental health

#### **Medical Cannabis**

- Largest provider of medical cannabis services in Canada
- Exclusively through telemedicine
- Partnering with all the top Licensed Holders
- Agreements with ~2K pharmacies



#### **PRODUCTS**

#### Home and Personal Healthcare Products

- Products supporting lifestyles of people with chronic pain
  - Orthotics, wheelchairs, prosthetics, mobility and home assist devices
- Sold through Slawner Ortho

## Cannabis Health Products (CHPs)

- New consumer product market
- Potential size >\$2 billion<sup>1</sup>
- Working with pharmacies to develop co-branded products
- Distribution network for a multi billion-dollar product category



## The Opportunity

## Fragmented chronic pain industry

Opportunity to roll up industry - accretive acquisitions to build on existing infrastructure

Target-rich M&A environment

#### Partnering Opportunities

Workers Comp, unions, insurance companies, family medical practices, allied health, mental health, Licensed Holders, First Nations, government, clinical trials



#### Pharmacy Partnerships

Patient assessments for medical cannabis; Cannabis Health Products (CHPs) development and distribution

#### Cannabis 3.0 incl. CHPs

Focus on medical - including CHPs;
Building CHP product category with pharmacy partners – distribution network for a new, multi billion-dollar product category



## Chronic Pain - A Large and Growing Problem

#### **Prevalent**

1 in 5 Canadian adults experience chronic pain <sup>1</sup>

# <u>ılı.</u> 0 0

#### **Burdensome**

>\$50 billion in health care resources and productivity losses <sup>2</sup>

#### Lack of specialists

Specialized pain services are largely inaccessible

#### **Under capacity**

1-3 Years average wait time for treatment at publicly-funded pain clinics in Canada <sup>3</sup>

 <sup>1</sup> Schopflocher et al., 2011; Reitsma et al., 2011; Steingrimsdottir et al., 2017, Canadian Pain Task Force Report, June 2019
 2 https://www.benefitscanada.com/benefits/health-benefits/chronic-pain-costs-employers-52439
 3 http://www.canada.com/health/live+this+life+pain+Canadians+with+chronic+pain+struggling+find+help+hope/5485154/story.html

## Growth Through Acquisition



- Preliminary projections indicate as many as 8.3 million Canadians may live with chronic pain by 2025 and as many as 9.0 million by 2030 <sup>1</sup>
- By 2030, the estimated direct costs will rise to \$20.5 - \$23.4 billion and indirect costs to \$31.5 billion <sup>1</sup>

- Immediate opportunities
  - ~10 targets with combined >\$150 million revenue
  - Interventional pain management
- Other Allied Health (chiro, physio, massage) targets for acquisiton or partnering
- Mental Health discussions ongoing
- Goal is to be come the leading provider of pain management services in Canada



## Growth Through New Products - Cannabis 3.0

In mid-2019, the federal government launched a consultation to seek feedback on the introduction of a new category of health products with cannabis, referred to as Cannabis Health Products (CHPs). If implemented, this regime would have the potential to create a new market for cannabis products in Canada.




Cannabis 3.0 - Bringing the benefits of cannabis derivatives (e.g. CBD, CBG) into mainstream health products

NPA's <sup>1</sup> pitch to the CDN government – "(P)harmacists have an important role in providing clinical information to patients at the point of sale." January 2021



Pharmacies have limited or no experience with this new consumer packaged goods category

 PHC is a credible partner for pharmacies – medical/scientific foundation, expertise in medical cannabis, strong ecosystem for product development, valued partner with Licensed Holders





## Pharmacies - Important Access Points



#### People see pharmacists more regularly than their physicians

Pharmacists see patients with chronic conditions up to 5-8 times more than primary care doctors for the treatment of chronic conditions 1



#### People want to ask pharmacists about cannabis

Canadians are strongly in favour of pharmacist dispensing of medical cannabis and recognize that it would improve patient safety and oversight 2





#### People trust pharmacists' guidance

92% of Canadians believe pharmacists play an essential or important role in Canada's health care system<sup>3</sup>

## Pharmacy Agreements





Agreements with pharmacy partners representing ~2,000 locations

Two key iniatives:

- Education of pharmacists in cannabis
- Access to medical cannabis clinical expertise for their patients





Access to medical cannabis product expertise:

 43,600 licensed pharmacists working in more than 11,400 pharmacies <sup>1</sup>

CHP product development in discussion





















CanTabs stillar









Forecast legal changes to CBD market worth >\$2 billion<sup>1</sup>

Profit margins can be higher than the average for other consumer goods such as alcohol, beer, wine, soft drinks and cigarettes <sup>2</sup>















## Bringing CHPs to Pharmacies



## Growth Drivers





Acquisition of clinics and patients including interventional and allied health



Regional market expansion of clinics in Canada

 Expand new clinical services to existing clinics including mental health



Sign additional pharmacy agreements for new patient consultations, education, CHPs



U.S. and international opportunities for new revenue streams

## Financial Overview



#### Revenue (\$million) 1

	9 months	12 months
	2021	2020
Provincial Revenue	\$ 4.1	\$ 5.9
Cannabis Revenue	2.5	3.9
Product Sales	1.9	2.2
Non-Insured Billings	<u>0.3</u>	<u>0.5</u>
	\$ 8.8	\$ 12.5

#### Patient Visits<sup>3</sup>

	2021	2020	Diff.	%
Cannabis	51,657	47,527	4,130	9%
Silver Pain	14,667	14,073	594	4%
Slawner Ortho	11,957	10,776	1,181	11%
NMI	<u>3,226</u>	<u>1,139</u>	2,087	<u>183%</u>
	81,507	73,515	7,992	11%









## Provincial Billings 46.6%


- Physician billings
- ~20% gross margins
- Cannabis Billings 28.4%
- Education and marketing revenue
- 100% gross margins

#### Product Sales 21.6%

- Quebec orthopaedic sales
- ~70% gross margins

### Non-Insured Billing 3.4%

- Patient private pay
- ~70% gross margins



<sup>1.</sup> Unaudited revenue figures include management's best estimate of adjusted revenue if all acquisitions occurred January 1st in each year and if the Manitoba joint venture revenues were consolidated.

<sup>2.</sup> Gross margins on Provincial Billings expected to increase as further integration of recent acquisitions occurs.

<sup>3.</sup> Patient figures include management's best estimate if all acquisitions occurred January 1st in each year.



## Comparable Companies

Clinic Based Healthcare Providers										
In CAD Millions except multiples										
	Market	<b>Enterprise</b>	Rev	<u>enue</u>	<u>EBI</u>	TDA	EV / R	<u>evenue</u>	EV / E	<b>BITDA</b>
	Capitalization	Value	2021	2022	2021	2022	2021	2022	2021	2022
Akumin Inc	\$135	\$1,865	\$963	\$1,028	\$207	\$250	1.9x	1.8x	9.0x	7.5x
WELL Health Technologies Corp	\$980	\$1,389	\$488	\$524	\$100	\$115	2.8x	2.6x	13.9x	12.1x
Medical Facilities Corp	\$321	\$546	\$517	\$495	\$125	\$130	1.1x	1.1x	4.4x	4.2x
CloudMD Software & Services Inc	\$224	\$206	\$191	\$222	(\$2)	\$3	1.1x	0.9x	N/A	78.4x
Greenbrook TMS Inc	\$82	\$103	\$96	\$126	(\$4)	\$14	1.1x	0.8x	N/A	7.2x
Empower Clinics Inc	\$85	\$85	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MCI Onehealth Technologies Inc	\$71	\$77	\$62	\$71	\$1	\$7	1.2x	1.1x	97.0x	11.4x
Skylight Health Group Inc	\$50	\$62	\$48	\$59	(\$9)	(\$2)	1.3x	1.1x	N/A	N/A
NeuPath Health Inc <sup>1</sup>	\$25	\$26	\$60	N/A	\$3	N/A	0.4x	N/A	8.2x	N/A
Jack Nathan Medical Corp	\$15	\$13	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Average							1.4x	1.4x	26.5x	20.1x
Median							1.2x	1.1x	9.0x	9.4x
Pathway Health Corp <sup>2</sup>	\$17	\$14	\$12	N/A	(\$4)	N/A	1.2x	N/A	N/A	N/A
Source: Refinitiv, February 10, 2022										

<sup>1.</sup> Estimated revenue and EBITDA figures based on annualizing the reported YTD Q3 2021 results.

<sup>2.</sup> Estimated revenue and EBITDA figures based on annualizing the reported YTD Q3 results and adjusting the figures to include management's best estimate of the results if all acquisitions occurred on January 1st and if the Manitoba joint venture revenues were consolidated.



## Cap Structure

	Percentage	Shares
Investor Group	Ownership	Outstanding
Insiders	55.7%	52,171,818
Other shareholders	44.3%	41,550,267
GRAND TOTAL	100%	93,722,085







#### Leading partner with Canadian Pharmacies on Medical Cannabis

- Signed 6 agreements with some of the nation's largest retail pharmacies > becoming the leading partner for pain services and products for thousands of Canadian pharmacies
- In discussion with several national pharmacy companies on CHP development, branding and distribution in preparation for Cannabis 3.0



#### Largest out-of-hospital chronic pain clinic in Canada

- One of the leading and most comprehensive out-of-hospital pain management businesses in Canada
- 6 acquisitions since January 2019
- Revenue has grown from \$600K to >\$12 million in 3 years. 1
- Developing a unique IT platform allowing the company to scale pharmacy initiative, improve patient engagement and expand its telemedicine services



#### Proven management

Expertise and experience in healthcare, cannabis, M&A, capital markets





## Contact Information

#### Wayne Cockburn

President

(905) 505-0770

wayne.cockburn@pathwayhealth.ca 🖄

#### **Investor Relations**

#### **Robin Cook**

(416) 809-1738

robin.cook@pathwayhealth.ca 🙊



## Appendix






## Ontario College of Pharmacists

"As medication therapy experts, pharmacists are in a unique position to provide quality and effective patient care for those who consume cannabis. This may take place through educating patients about the consumption of cannabis ... and through collaboration with other health care professionals to enhance patient safety.

(T)he Ontario College of Pharmacists would not oppose any federal or provincial legislation that would permit the dispensing of non-smoked forms of cannabis for medical use within pharmacies..."




August 2016





## Evolution of Pharmacy & Cannabis (04/17 - 05/19)



#### Pathway Health

## Evolution of Pharmacy & Cannabis (05/19 - present)

